Several thousand young men and families of boys diagnosed with gynecomastia are currently pursuing Risperdal lawsuits as a result of the drug maker’s failure to adequately warn that use of the medication may cause male breast growth.
Johnson & Johnson has agreed to settle a small number of Risperdal breast growth cases that were set for “bellwether” trials in 2016, and has been hit with some substantial jury awards for withholding information about the potential Risperdal problems. However, the drug maker has not reached any global or wide-reaching settlements and continues to indicate that it will defend the cases and evaluate whether to settle on a case-by-case basis.
In February 2015, the first Risperdal trial went before a Philadelphia jury, resulting in a $2.5 million damage award for a 20 year old man who suffered gynecomastia breast growth after using the medication for treatment of autism when he was 8 years old.
Two additional Risperdal bellwether trials in Pennsylvania have resulted in substantial jury awards for boys and young men diagnosed with male breast growth, including a verdict of $1.75 million in November 2015 and $500,000 in December 2015.
In July 2016, a jury ordered Johnson & Johnson to pay $70 million to the family of a boy diagnosed with gynecomastia following use of Risperdal starting when he was five years old.
According to evidence presented at these trials, Johnson & Johnson’s Janssen unit knew about the Risperdal gynecomastia risk as early as 2001, yet failed to warn consumers and the medical community.
Following that massive verdict, Johnson & Johnson has reportedly reached agreements to settle Risperdal cases set for trial to begin in late 2016 and early 2017, yet details of those agreements have not been released.
While these settlements and recent verdicts in early “bellwether” trials are not binding on other claims in the Risperdal litigation, they are designed to help gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout other cases and our lawyers feel confident that Johnson & Johnson will have to negotiate fairly with all individuals diagnosed with gynecomastia to avoid hundreds of individual trial dates.
As part of any Risperdal negotiations to settle additional cases, a number of case-specific factors will be considered in determining how much compensation each child diagnosed with gynecomastia breast growth may receive, including an evaluation of what a jury may award if the case goes to trial.
There are no set Risperdal settlement amounts or established calculation of damages each boy will be entitled to receive.
Factors taken into account include the nature of the injury in each case and the impact of the Risperdal breast growth on the boy’s life.
If a case proceeds to trial, the jury will hear evidence specific to that plaintiff’s gynecomastia diagnosis and any award of damages will be based on: The extent and duration of the injury suffered.
A substantial amount of evidence suggests that Johnson & Johnson knew or should have known about the risk of gynecomastia from Risperdal side effects. However, information was withheld from families and the medical community.
While ignoring the devastating impact use of Risperdal may have on some boys’ lives, the drug maker continued to aggressively market the medication for pediatric use, placing their desire for profits before the safety and well-being of consumers.
The impact of gynecomastia from Risperdal can have a serious impact on adolescent boys and leave them with long-lasting effects throughout the lifetime. In addition to the physical injury caused by the development of breasts and the need for surgical removal in some cases, researchers have documented that gynecomastia can have a significant negative impact on:
Before it became available as a generic in 2008, Risperdal was a blockbuster medication, generating global sales of $4.5 billion in 2007. However, Johnson & Johnson has faced substantial legal problems over their Risperdal promotions, which illegally marketed the drug for off-label uses that were never approved or established as safe and effective. In addition to some settlements over Risperdal male breast growth, Johnson & Johnson has plead guilty to criminal charges that it illegally promoted Risperdal and has agreed to pay billions of dollars in fines and civil liability penalties.
Risperdal is used to treat certain mental/mood disorders (such as schizophrenia, bipolar disorder, irritability associated with autistic disorder). This medication can help you to think clearly and take part in everyday life. Risperdal belongs to a class of drugs called atypical antipsychotics.